



Division of Health Policy and Insurance Research  
The Harvard Medical School  
Fellowship in Health Policy and Insurance Research  
(Formerly Fellowship in Pharmaceutical Policy Research)

## Fellows

### **Alessandra Ferrario, PhD**

**2017-2018**

Dr. Alessandra Ferrario received her doctorate from the Department of Social Policy, London School of Economics and Political Science in 2017 and was awarded a fellowship from the prestigious Swiss National Science Foundation.

During her fellowship, she will study the intensity of end-of-life care over time and its determinants among women with breast cancer who are insured by a large commercial health insurer in the US.

### **Christine Leopold, PhD**

**2014-  
present**

**Dr. Leopold** is a Post-Doctoral Research Fellow in the Department of Population Medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute. She received an Erwin Schroedinger stipend from the Austrian Science Fund as well as a Thomas O. Pyle Research Scholarship from Harvard Medical School. Currently she works on various studies in which she assess the impact of policy changes (regulatory or coverage) on the utilization of metastatic breast cancer treatments by looking at trends in claims data. In addition, Dr. Leopold performed a qualitative study on the adaptability of pharmacy benefits systems to the current challenges of high-cost specialty medicines in various high-income countries. Her main research interests include ethical considerations in pharmaceutical pricing and reimbursement, evidence-based decision-making in pharmaceutical policy as well as the evaluation of the pharmaceutical policies' impact on affordability and availability of medicines. Prior to joining the Department of Population Medicine at Harvard Medical School she co-led the Austrian Centre for Rare Disease as well as the European Network of public authorities of Pharmaceutical Pricing and Reimbursement Information (PPRI) at the Department of Health Economics at the Austrian Health Institute / WHO Collaborating Center for Pharmaceutical Pricing and Reimbursement Policies. She holds a doctorate in Pharmaceutical Policy from Utrecht University, Utrecht Institute for Pharmaceutical Science / WHO Collaborating Centre for Pharmaceutical Policy and Regulation in the Netherlands and a Master of Science degree from Bocconi University in Italy.

### **Selected Publications:**

**Leopold C**, Zhang F, Mantel-Teeuwisse AK, Vogler S, Valkova S, Ross-Degnan D, Wagner AK. Impact of pharmaceutical policy interventions on sales of antipsychotic medicines in Finland and Portugal: interrupted time series analyses. *International Journal of Equity in Health*. In press.

**Leopold C**, Mantel-Teeuwisse AK, Vogler S, Valkova S, de Joncheere, Wagner AK, Ross-Degnan D, Laing RO. Impact of pharmaceutical policy measures implemented in response to the 2008 recession on medicine consumption in Europe. WHO Bulletin. In press.

**Leopold C**, Mantel-Teeuwisse AK, Vogler S, de Joncheere K, Leufkens HGM, Laing RO. Is Europe heading to a common price level for on-patent medicines? A price comparison among 15 Western European countries. Health Policy. 2013 Sep 8 [Epub ahead of print].

**Leopold C**, Mantel-Teeuwisse AK, Seyfang L, Vogler S, de Joncheere K, Laing RO, Leufkens HGM. Impact of external price referencing on medicine prices – a price comparison among 14 European countries. Southern Med Review. December 2012; 5(2):34-41.

**Leopold C**, Vogler S, Mantel-Teeuwisse A, de Joncheere K, Leufkens HGM, Laing R. Differences in external price referencing in Europe – A descriptive overview. Health Policy. 2012;104(1):50-60.

---

## PAST FELLOWS

**Isabel CM Emmerick, MS, PhD**

**2012-2016**

Dr. Emmerick was a post-doctoral fellow in the Pharmaceutical Policy Research Fellowship at the Department of Population Medicine. Her research is in the area of improving health systems in developing countries, including research of the factors related to use of medicines and impacts of pharmaceutical policies on utilization. Her primary area of interest is to evaluate the impact of the four Brazilian subsidy policies regarding access to medicines.

As a researcher at the Center for Pharmaceutical Policies (NAF) of ENSP/FIOCRUZ in Brazil, a PAHO/WHO Collaborating Center, she participated in the formulation and support to evaluation of pharmaceutical policies, not only in Brazil but also in other countries of the Region of the Americas and Africa, and worked in permanent exchange with the medicine programs of PAHO and WHO.

Dr. Emmerick received her Bachelor of Science in Pharmacy degree from the Universidade Federal do Rio de Janeiro, Brazil and her Masters of Science and Doctorate of Science degrees in Public Health from the National School of Public Health, Oswaldo Cruz Foundation, Brazil. She also was a research scholar in the Department of Population Medicine Drug Policy Research Group in from 2009 until 2010.

### Publications

**Emmerick ICM**, Oliveira MA, Luiza VL, Azeredo TB, Bigdeli M. Access to medicines in Latin America and the Caribbean (LAC): a scoping study. BMJ Open 2013;3:e002224. doi:10.1136/bmjopen-2012- 002224.

**Emmerick ICM**, Luiza VL, Camacho, Camacho LAB; Ross-Degnan D. Access to medicines for acute illness in three middle income countries in Central America. *Rev Saúde Pública* 2013;47(6):1069-79.

**Emmerick ICM**, Luiza VL, Pepe VL. Pharmaceutical services evaluation in Brazil: broadening the results of a WHO methodology. *Ciencia & Saude Coletiva* 2009;14(4):1297-306.

Pinto Cdu B, Miranda ES, **Emmerick IC**, Costa Ndo R, Castro CG. Medicine prices and availability in the Brazilian Popular Pharmacy Program. *Rev Saude Publica* 2010;44(4):611-9.

Miranda, Elaine Silva; Pinto, Claudia Du Bocage Santos; REIS, Andre Luis de Almeida dos; **Emmerick, Isabel Cristina Martins**; Campos, Monica Rodrigues; Luiza, Vera Lucia; Osorio-De-Castro, Claudia Garcia Serpa. Lessons learnt from conducting a medicine price survey in multiple regions of Brazil. *WHO Essential Medicines Monitor*, issue 4, p. 1-4, April 2010.

Miranda ES, Pinto Cdu B, dos Reis AL, **Emmerick IC**, Campos MR, Luiza VL, Osorio-de-Castro CG. Availability of generic drugs in the public sector and prices in the private sector in different regions of Brazil. *Cad. Saúde Pública*. 2009;25(10):2147-58.

---

**Rebecca Haffajee, JD, MPH, PhD**

**2012-2016**

Dr. Haffajee is an Assistant Professor of Health Management and Policy at the University of Michigan School of Public Health.

After completing her JD and MPH at Harvard in 2006, Rebecca practiced as a health care associate in the law firm of Ropes & Gray LLP for three years, where she advised domestic health care providers on regulatory compliance and reimbursement matters. From 2009-2010, she served as a Law Fellow at the O'Neill Institute for National and Global Health Law at Georgetown University Law Center. Rebecca entered the Harvard PhD Program in Health Policy in 2010 with a concentration in Evaluative Science and Statistics and received her doctorate in May 2016.

Applying sophisticated analytical methods from econometrics, epidemiology, and public health law research, Rebecca's work combines detailed legal analysis with empirical investigations of the relationships between law and health. Her doctoral work focused on evaluating the effects of behavioral health legal interventions. She recently completed a longitudinal assessment of the effects of the federal Mental Health Parity and Equity Addiction Act (MHPAEA) on mental health treatment and outcomes.

During her fellowship in the Department of Population Medicine, Rebecca worked on an empirical analysis of the intended and unintended impacts of state prescription drug monitoring program mandates that require physicians to participate in querying the programs before prescribing controlled substances. Her work has been funded by the Robert Wood Johnson Foundation, the National Institute of Mental Health, the Department of Population Medicine, and Harvard University.

**Publications:**

**Haffajee RL.** Preventing opioid abuse with prescription drug monitoring programs: a framework for evaluating the success of state public health laws. *Hastings Law Journal* 2016;67(6) (forthcoming).

**Haffajee RL,** Jena AB, Weiner SG. Mandatory use of prescription drug monitoring programs. *JAMA* 2015;313(9):891-892.

**Haffajee RL,** Parmet WE, Mello MM. What is a public health “emergency”? *N Engl J Med* 2014;371(11):986-988.

**Haffajee RL,** Bloche GM. The FCTC and the psychology of tobacco control. *Asian J WTO Int'l Health L. & Pol'y* 2010;5(1):87-113.

**Haffajee RL.** The potential use of joint criminal enterprise theory in prosecuting crimes of rape and sexual violence at the ICTR. *Harvard J Law & Gender* 2006;29(1):201-221.

---

**Ming Hu, PhD**

**2013-2014**

Dr. Hu is an associate professor in the Department of Clinical Pharmacy and Pharmacy Administration at West China School of Pharmacy, Sichuan University. She is also the recipient of the prestigious China Medical Board Faculty Development Award. Ming conducted a range of research projects in the effectiveness evaluation of pharmaceutical policies, and economic evaluation of clinical pharmacy practice in the past 10 years. During her 6-month Pharmaceutical Policy Research Fellowship in the Drug Policy Research Group, Ming focused on the performance evaluation of the National Essential Medicine System in China.

---

**Rosarin Sruamsiri, BPharm, MBA, PhD**

**2013-2014**

Dr. Sruamsiri is a Health Economist at Janssen (Johnson & Johnson). Her research interests included evidence-based decision making in health care, pharmacoeconomic and outcomes research. Rosarin is also interested in the evaluation of health policy with a particular focus on observational data. During her Pharmaceutical Policy Research Fellowship year in the Drug Policy Research Group, Rosarin’s research focused on the evaluation of one of the Thailand national policies, “High-cost medicine: E2 access program” which aims to increase access to expensive medicine for patients in need. She evaluated the effects of this policy on medicine utilization and health care costs in Thailand.

**Publications:**

**Sruamsiri R,** Wagner AK, Ross-Degnan D, Lu CY, Dhippayom T, Ngorsuraches S, Chaiyakunapruk N. Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis. *BMJ Open.* 2016 Mar 17;6(3):e008671. doi: 10.1136/bmjopen-2015-008671.

---

**Chih-Sheng (Jason) Hsu, MSc, PhD**

**2011-2012,  
2013-2014**

Dr. Hsu is a pharmacist and a public health researcher in Taiwan National Center for Pharmaceutical Regulatory Science. Jason holds a B.A. in pharmacy, M.Sc. in technology management and a Ph.D. in international business. Jason’s professional field includes

quantitative medical regulatory science and decision science. His regulatory science research focuses on the impacts of pharmaceutical policies on medicine utilization and clinical outcome; his decision analytic work focuses on risk-benefit assessment and statistical/economic evaluation of medicine. During his Pharmaceutical Policy Research Fellowship years in the Drug Policy Research Group, Jason's main fellowship project was a comparison of impacts of safety warnings and Risk Evaluation & Mitigation Strategies (REMS) on drug utilization and clinical outcome between USA and Taiwan.

**Publications:**

**Hsu JC**, Lu CY, Wagner AK, Chan KA, Lai MS, Ross-Degnan D. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study. *Health Policy*. 2014 Jun;116(2-3):196-205.

---

**Laura Faden Garabedian, PhD**

**2012-2014**

Dr. Garabedian is an assistant professor in the Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute. She is a member of the Division of Health Policy and Insurance Research (formerly the Drug Policy Research Group).

Dr. Garabedian's research focuses on the robust evaluation of global and domestic health insurance reforms, insurer-led health system delivery reforms and pharmaceutical policies. She is also interested in the evaluation and development of analytic methods for health policy research, with a particular focus on observational data methods for comparative effectiveness research.

Dr. Garabedian received her PhD in Health Policy from Harvard University, with a specialization in evaluative science and statistics. She was a pre-doctoral Pharmaceutical Policy Research Fellow and a post-doctoral Pyle Fellow at DPM. Prior to Harvard, Dr. Garabedian worked as a research analyst at the Tufts Center for the Study of Drug Development. She has an MPH from Tufts and a BA from Boston University.

**Publications:**

**Faden L**, Vialle-Valentin C, Ross-Degnan D, Wagner A. Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence. *Health Policy*. 2011; 100(2-3):134-43. PMID: 21185616

**Garabedian LF**, Ross-Degnan D, Ratanawijitrasin S, Stephens P, Wagner AK. Impact of universal health insurance coverage in Thailand on sales and market share of medicines for non-communicable diseases: an interrupted time series study. *BMJ Open*. 2012; 28;2(6). PMID: 23192243; PMCID: PMC3533018.

---

**Huseyin Naci, PhD**

**2012-2014**

Dr. Huseyin Naci is an Assistant Professor of Health Policy at The London School of Economics and Political Science (LSE). Huseyin's academic interests include research design, comparative effectiveness research, drug regulation, and health policy evaluation. His methodological research focuses on the strengths and weaknesses of study designs in determining the benefits and harms of health care interventions and policies. He is

particularly interested in the application of evidence generated from randomized trials, observational studies, and network meta-analyses to decision-making in health policy and clinical practice.

Huseyin's policy-relevant research focuses on the unintended consequences of health policies; market entry requirements for new health technologies; economic access to medications; and the role of health care professionals in caring for individuals with multiple chronic conditions.

Prior to starting his research at LSE Health, Huseyin conducted research in the areas of international health, mental health, and international development at the World Health Organization and Johns Hopkins University. Most recently, he was a Thomas O. Pyle Fellow in Population Medicine at Harvard University (2013-2014) and a Fellow in Pharmaceutical Policy Research at Harvard Medical School and Harvard Pilgrim Health Care Institute (2012-2013), both in Boston, USA.

Huseyin received his Doctor of Philosophy (PhD) in Pharmaceutical Policy and Economics from the London School of Economics and Political Science (London, UK); his Master of Science in Public Health (MSPH) degree in International Health, with a focus on Health Economics from the Johns Hopkins University Bloomberg School of Public Health (Baltimore, MD, USA); and his Bachelor of Arts degree in Biochemistry from Knox College (Galesburg, IL, USA).

#### **Publications:**

**Naci H**, Ioannidis JP. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. *BMJ* 2013;347:f5577.

**Naci H**, Soumerai SB, Ross-Degnan D, Zhang F, Briesacher BA, Gurwitz JH, Madden JM. Medication affordability gains following medicare part d are eroding among elderly with multiple chronic conditions. *Health Aff (Millwood)*. 2014;33(8):1435-43.

**Naci H**, Soumerai SB, Ross-Degnan D, Zhang F, Briesacher BA, Gurwitz JH, Madden JM. Persistent Medication Affordability Problems Among Disabled Medicare Beneficiaries After Part D, 2006-2011. *Med Care*. 2014. [Epub ahead of print].

**Naci H**, Dias S, Ades AE. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. *BMJ* 2014;349:g5741.

---

#### **Difei Wang, PhD**

**2012-2013**

Difei Wang was a postdoctoral fellow in the Pharmaceutical Policy Research Fellowship at Harvard Medical School and Pilgrim Healthcare Institute. He received his PhD in health policy in 2012 at Tongji Medical College, Huazhong University of Science and Technology in China.

Difei is specializing in evaluating the impact of pharmaceutical policy changes on the use of medicines in China. His research interests are in studying access to and use of medicines, the price and affordability of medicines, and the selection and coverage of medicines in the Chinese national health insurance system.

Difei's primary research topics during his fellowship year were evaluating the effects of China's essential medicines policy on outpatients medicine use and studying the impact of social health insurance policy changes on inpatient health service and drug utilization.

---

**Yu Fang, PhD****2012-2013**

Dr. Yu Fang joined the fellowship as a recipient of the prestigious China Medical Board Faculty Development Award. He is an associate professor in the Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Health Science Center, Xian Jiaotong University. He is also the vice-dean of the School of International Education and the director of the Center for Drug Safety and Drug Policy at the University. Dr. Fang is a member of International Pharmaceutical Federation (FIP) and International Health Economics Association (iHEA). He graduated from Xian Medical University and earned his MSc in Pharmacy Administration in 2004 from Xian Jiaotong University and PhD in Pharmacy Administration from Shenyang Pharmaceutical University in 2007. In 2007 Dr. Fang was a visiting scholar in the Department of Pharmaceutical Care & Health System, School of Pharmacy in the University of Minnesota. Dr. Fang's major research interests cover the areas of pharmaceutical policy and rational drug use in community setting. He published over 40 papers and was the editor or co-editor of 8 books.

**Publications:**

**Yu Fang**, Anita K Wagner, Shimin Yang, Minghuan Jiang, Fang Zhang, Dennis Ross-Degnan. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China. *Lancet Global Health*, 2013, 1(4): e227-e237.

**Yu Fang**. China should curb non-prescription use of antibiotics in the community. *BMJ*, 2014; 348: g4233.

---

**Matthew Frank****2011-2012**

Matthew Frank was a PhD candidate in Health Policy at Harvard University. He was a recipient of a National Science Foundation Graduate Research Fellowship. Matt graduated from Northwestern University with a double major in economics and history. He then worked for over a decade in finance and consulting, and also spent several years in the nonprofit sector. In June 2009, Matthew received a master of divinity degree from Harvard Divinity School, where his research focused on bioethics and public policy. Matt's fellowship research used both empirical and normative methods to assess how health insurance designs can improve quality and constrain spending while protecting access to care for vulnerable groups.

---

**Atle Fretheim, MD, PhD****2011-2012**

Dr. Fretheim is a Research Director Global Health Unit at the Norwegian Knowledge Centre for Health Services (<http://www.kunnskapssenteret.no/units/global-health-unit>). Atle is also an Associate Professor at the Institute of Health and Society, Faculty of Medicine, University of Oslo. Dr. Fretheim's research during his fellowship was on comparisons of results from cluster-randomized trials with those from analyses of interrupted time series data.

**Publication:**

**Fretheim A**, Soumerai SB, Zhang F, Oxman AD, Ross-Degnan D. Interrupted time-series analysis yielded an effect estimate concordant with the cluster-randomized controlled trial result. *J Clin Epidemiol.* 2013; 66: 883-7.

---

**Bao Liu, PhD****2011-2012**

Dr. Liu joined the fellowship as a recipient of the prestigious China Medical Board Faculty Development Award. His fellowship research was on analyzing health systems data to form health care and medicines policy in China. Dr. Liu is an associate professor in the Department of Health Economics, School of Public Health, Fudan University. He is a fellow of Chinese Price Association and member of Fudan University Commission of Planning and Development. Dr. Liu graduated from Shanghai Medical University and earned his MSc in Biostatistics in 2000 and PhD in Health Economics from Fudan University in 2003. Dr. Liu served as technical officer of the World Health Organization in the Department of Health Financing and Stewardship in 2001 and in the Department of Chronic Diseases and Health Promotion in 2005-2006, dedicating to the pursuit of global health systems performance assessment and the progress evaluation of global chronic disease prevention and control. In 2010 Dr. Liu was a visiting scholar in the Department of Health Policy and Management, Johns Hopkins School of Public Health. Dr. Liu's major research interests cover the areas of health economics, pharmaceutical economics, and public health policy. He published over 60 papers and was the editor or co-editor of six books.

---

**Meredith Chace, PhD****2010-2012**

Dr. Chace received her PhD in Health Policy from Harvard University, with a concentration in evaluation sciences and statistics. Meredith received a Master of Science degree in Health Policy and Management from the Harvard School of Public Health in 2006. Meredith's fellowship research focused on Medicare/Medicaid dual eligibles drug coverage as well as utilization and cost of care of patients with Multiple Sclerosis. She has worked as an analyst at three different companies focusing on claims data analysis for health outcomes research, health economics and pharmacoepidemiology. Her current research interests include health care access, nursing home care, and pharmaceutical policy.

**Publication:**

**Chace MJ**, Zhang F, Fullerton CA, Huskamp HA, Gilden D, Soumerai SB. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder. *J Clin Psychiatry.* 2012 Nov;73(11):1388-94. PMID: 23146199.

---

**Aakanksha H. Pande, PhD****2009-2011**

Dr. Pande is a Senior Health Economist at the World Bank Group with more than fifteen years experience working in low, middle and high income countries. She has expertise in topics related to the health impact of conflicts (Syria, Yemen etc), health sector reform,



universal health coverage, and non communicable diseases, quality of care. She brings rigorous methodological expertise in impact evaluation, econometric analyses, health system diagnoses, and development of strategy.

During her fellowship, her research involved with using quasi evaluative methods to inform health policy and towards this end she has designed impact evaluations of AIDS program in South Africa and Uganda. She is a co-author of "Handbook for evaluating real world HIV programs" (World Bank, forthcoming) and has authored papers in the academic and non academic press (including an op-ed on her other passion -- the game of cricket-- for the New York Times!). She holds a masters and doctorate from Harvard University, an undergraduate degree from Yale University, and was a Fox International Fellow at Cambridge University in UK.

#### **Publications:**

Pérez-Cuevas R, Doubova SV, Suarez-Ortega M, Law M, **Pande AH**, Escobedo J, Espinosa-Larrañaga F, Ross-Degnan D, Wagner AK. Evaluating quality of care for patients with type 2 diabetes using electronic health record information in Mexico. *BMC Med Inform Decis Mak.* 2012;12:50. PMID: 22672471.

**Pande AH**, Ross-Degnan D, Zaslavsky AM, Salomon JA. Effects of healthcare reforms on coverage, access, and disparities: quasi-experimental analysis of evidence from Massachusetts. *Am J Prev Med.* 2011;41(1):1-8. PMID: 21665057.

---

#### **Bin Jiang, PhD**

**2010-2011**

Dr. Bin Jiang is an associate professor of Pharmacy Administration in the Department of Administrative and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center. Dr. Jiang has a wide range of teaching and research experiences in pharmaceutical regulation and policy in China. Dr. Jiang was the recipient of the prestigious China Medical Board Faculty Development Award. Bin Jiang's fellowship research focused on Chinese health care reform.

---

#### **Li Yang, PhD**

**2010-2011**

Dr. Li Yang is an associate professor at Department of Health Policy and Management, School of Public Health, Peking University. She also serves as the Beijing chapter representative for the ISPOR Asia Executive Committee and the editor of Chinese Journal of Pharmaceutical economics. Her scientific expertise is pharmaceutical policy and pharmacoeconomics, economic impact of chronic diseases and aging issue. She has directed numerous projects on drug pricing, quality of life evaluations and cost-effectiveness analyses, and written and lectured in pharmacoeconomics. She was involved in monitoring and assessing the Chinese Essential Medicine Policy in 13 provinces funded by MOH and AuID. She holds a Ph.D in health economics from Fudan University and has been a post-doctoral researcher in the University of Vienna. Dr. Yang was also the recipient of the prestigious China Medical Board Faculty Development Award she was a fellow in Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute.

Dr. Li Yang joined the Fellowship from Peking University where she is an associate professor in the Department of Health Policy and Management. Dr. Yang was also the

recipient of the prestigious China Medical Board Faculty Development Award. Li Yang's fellowship research centered on medicines policy in China.

---

**Sheila Reiss Reddy, MSc, RPh, PhD**

**2007-2011**

Sheila Reddy is Director of Health Services Research at Partnership for Health Analytic Research. Dr. Reddy is a health services researcher and pharmacist with over 10 years of experience in health policy research, project management, and patient care delivery. Sheila's research has focused on health care affordability, exploring the impact of high cost sharing on access to care and on household economic stability. Core competencies include impact evaluation, health economics, outcomes research, real world data analysis, study design and outcomes measurement, global health, program evaluation management, managed care, and pharmaceutical policy.

Prior to her career in research and evaluation, Sheila practiced pharmacy in the US and worked in public health in Sub-Saharan Africa, focusing the latter on improving maternal and child health, vaccination coverage, HIV prevention, and water and sanitation for rural communities. These earlier experiences helped to inform her understanding of diverse health systems and spurred her interest in generating and using evidence to advance health policies, programs, and treatments.

Dr. Reiss received her PhD in health policy at Harvard University. Her research interests broadly include global pharmaceutical policy and disparities in access to care. She has examined how best to measure health care affordability by assessing the validity of widely used measures of economic burden due to health care payments; and she also studied whether insurance plans with the highest levels of cost-sharing reduce access to essential medicines. Her fellowship research focused on U.S. and global health policy research on health care affordability, insurance design and coverage, access to essential care and medicines, and household financial burden due to out-of-pocket health spending.

---

**Publications:**

**Reiss SK**, Ross-Degnan D, Zhang F, Soumerai SB, Zaslavsky AM, Wharam JF. Effect of Switching to a High-Deductible Health Plan on Use of Chronic Medications. *Health Serv Res.* 2011;46(5):1382-401. PMID: 21413983.

Wagner AK, Graves AJ, **Reiss SK**, Lecates R, Zhang F, Ross-Degnan D. Access to care and medicines, burden of health care expenditures, and risk protection: results from the World Health Survey. *Health Policy.* 2011;100(2-3):151-8. PMID: 20828854.

---

**Brian Serumaga, MPH, PhD**

**2009-2010**

Dr. Serumaga is a technical advisor at John Snow Inc, and associate lecturer in primary care at University of Nottingham Medical School, UK. He holds a doctorate in primary health care and an MPH from the University of Nottingham and a Pharmacy degree. In 2009-2010, His fellowship research focused on improving the quality of health care in both developed and developing countries. He also works on identifying and analyzing the effects of policy, regulatory frameworks, and health system environments on quality of care and access to medicines. He is a member of the pharmaceutical society of Uganda, the Cochrane systematic review group on patient safety, the WHO access to medicines research

network, the international society on pharmacoepidemiology and drug safety and the drug utilization research group.

**Publications:**

**Serumaga B**, Ross-Degnan D, Avery AJ, Elliott RA, Majumdar SR, Zhang F, Soumerai SB. Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study. *BMJ*. 2011;342:d108. PMID: 21266440.

---

**Katy Backes Kozhimannil, MPA, PhD**

**2007-2010**

Dr. Kozhimannil received her PhD in Health Policy from Harvard University. Her research interests include applied program and policy evaluation, maternal health services research, mental health care, state health policy, and disparities. She has a particular interest in policy analysis and evidence-based policy formulation and has had the opportunity to contribute to policy debates in New Jersey, Massachusetts, and Minnesota based on her research. For example, her 2011 paper on the impacts of New Jersey's postpartum depression legislation contributed to discussions of the implementation of the 2010 Act Relative to Post Partum Depression (PPD) in the state of Massachusetts. In 2010, Dr. Kozhimannil joined the Division of Health Policy and Management at the University of Minnesota School of Public Health as an Assistant Professor.

Dr. Kozhimannil's recent research findings have been covered national media, including the New York Times, ABC News, U.S. News and World Report, and the Huffington Post, and a 2013 paper she authored led to legislation authorizing Minnesota's Medicaid program to reimburse trained doulas for continuous labor support.

**Publications:**

Ross-Degnan D, **Kozhimannil KB**, Payson A, Aupont O, LeCates R, Briggs J, Chalker J, Acharya K, Zimicki S. Improving community use of medicines in the management of child illness: a guide to developing interventions. Cambridge, MA: Management Sciences for Health; 2008.

**Kozhimannil KB**, Pereira MA, Harlow BL. Association between diabetes and perinatal depression among low-income mothers. *JAMA* 2009;301:842-847.

**Kozhimannil KB**, Valera MR, Adams AS, Ross-Degnan D. The population-level impacts of a national health insurance program and franchise midwife clinics on achievement of prenatal and delivery care standards in the Philippines. *Health Policy* 2009;92:55-64.

**Kozhimannil KB**, Adams AS, Soumerai SB, Busch AB, Huskamp HA. New Jersey's efforts to improve postpartum depression care did not change treatment patterns for women on Medicaid. *Health Aff (Millwood)* 2011 Feb;30(2):293-301.

**Kozhimannil KB**, Huskamp HA, Graves AJ, Soumerai SB, Ross-Degnan D, Wharam JF. High-deductible health plans and costs and utilization of maternity care. *American Journal of Managed Care*. 2011;17(1)e15-e24.

**Kozhimannil KB**, Trinacty CM, Busch AB, Huskamp HA, Adams AS. Racial/ethnic disparities in postpartum depression care among low-income women. *Psychiatric Services*. 2011 Jun;62(6).

---

**Ashley J. Beard, MPH, PhD**

**2008-2010**

Dr. Beard was a Thomas O. Pyle Research Fellow at the Department of Population Medicine. She holds an MPH in Health Behavior and Health Education at the University of North Carolina at Chapel Hill and her PhD in Pharmaceutical Outcomes and Policy at the UNC School of Pharmacy. Dr. Beard's research interests focus on the quality and context of care for adults with multiple chronic illnesses. She is particularly interested in the intersection of informal and formal systems of care and ways to maximize the utility of both to improve medication use and patient health outcomes. Her fellowship research included examination of medical visit communication about medications, the influence of family and friend caregivers, and development of innovative interventions to facilitate medication use and caregiver support of adults with multiple chronic illnesses. In 2010, Dr. Beard became a faculty member in the University Michigan Health Services Research and Development Program.

**Publications:**

Harrold LR, Peterson D, **Beard AJ**, Gurwitz JH, Briesacher BA. Time trends in medication use and expenditures in older patients with rheumatoid arthritis. *Am J Med*. 2012;125(9):937.e9-15. PMID: 22682794.

**Beard AJ**, Sleath B, Blalock SJ, Roth M, Weinberger M, Tudor G, Chewing B. Predictors of rheumatoid arthritis patient-physician communication about medication costs during visits to rheumatologists. *Arthritis Care Res (Hoboken)*. 2010 May;62(5):632-9. PMID: 20191466.

---

**Christine Yi-Ju Lu, BPharm, MSc, PhD**

**2007-2008**

Dr. Lu is an Assistant Professor in the Department of Population Medicine. She is a pharmacist, pharmacoepidemiologist, and health policy researcher. Dr. Lu received a MSc (Biopharmaceuticals) and a PhD in Clinical Pharmacology from the University of New South Wales, Australia. Her current research focuses on access to biologic medicines, genomic-based technologies, orphan drugs, and psychotropic medications. Since 2012, she also serves as Adjunct Senior Lecturer in the Faculty of Pharmacy, University of Sydney, Australia.

During her Fellowship, Dr. Lu examined the effects of prior authorization policies for atypical antipsychotic, anticonvulsant and cardiovascular medications on use of medications and health services among Medicaid beneficiaries.

**Publications:**

**Lu CY**, Ross-Degnan D, Soumerai SB, Pearson SA. Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature – 2001-2007. *BMC Health Services Research*. 2008; 8:75.

Adams AS, Zhang F, LeCates R, Graves AJ, Ross-Degnan D, Gilden D, McLaughlin T, **Lu CY**, Trinacty CM, Soumerai SB. Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees. *Arch Intern Med.* 2009;169:750-6.

**Lu CY**, Soumerai SB, Ross-Degnan D, Zhang F, Adams AS. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. *Med Care.* 2010; 48(1):4-9.

Law MR, **Lu CY**, Soumerai SB, Graves AJ, LeCates RF, Zhang F, Ross-Degnan D, Adams AS. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: Results of a longitudinal, population-based study. *Clin Ther* 2010;32(4):729-41

**Lu CY**, Adams AS, Ross-Degnan D, Zhang F, Zhang Y, Soumerai SB. Association Between Prior Authorization for Medications and Health Services Use by Medicaid Patients With Bipolar Disorder. *Psych Serv* 2011; 62(2):186-93

---

**Catherine E. Vialle-Valentin, MD, MHCM**

**2006-2008**

Dr. Catherine Vialle-Valentin, was Senior Research Associate in the Department of Population Medicine from 2008-2016. She received her medical degree in France where she is board certified in endocrinology. She holds a masters degree in health policy and management from the Harvard School of Public Health. Dr. Vialle-Valentin's research is in the area of international pharmaceutical policy evaluation. During her Fellowship, she completed a study to evaluate the role of community-based health insurance schemes on access to medicines in poor settings. At present, her work is centered on methods for measuring access to and rational use of medicines in developing countries. Her main focus continues to be the development and testing of a household survey to collect in-depth information on medicines used during acute and chronic conditions, and barriers to medicines access.

**Publication:**

**Vialle-Valentin CE**, Ross-Degnan D, Ntaganira J, Wagner AK. Medicines coverage and community-based health insurance in low-income countries. *Health Res Policy Syst* 2008;6:11.

---

**Michael R. Law, MSc, PhD**

**2006-2008**

Dr. Michael Law holds the Canada Research Chair in Access to Medicines, and is an Associate Professor in the Centre for Health Services and Policy Research, School of Population and Public Health, at the University of British Columbia.

Michael's research program focuses on pharmaceutical policy. His work focuses on access to and the use of prescription drugs, including the affordability of prescription drugs, private drug insurance, generic drug pricing, and the impact of pharmacist prescribing. His research program has attracted more than \$2.5 million in research funding, including 4 operating grants from CIHR as principal investigator.

He has been published in leading medical journals, including BMJ, Archives of Internal Medicine, and CMAJ. This work has been featured in news media such as New Scientist, Forbes, the Globe & Mail, and USA Today. He has also authored commentaries that have

appeared in the Toronto Star and Vancouver Sun. His research has had a major impact on generic drug pricing in Canada, leading to policy changes that have saved governments the country more than \$100 million every year.

Since his appointment at UBC he has received several notable awards, including a Distinguished Achievement Award from the UBC Faculty of Medicine (2012), the Labelle Lectureship at McMaster University, the 2011 Paper of the Year Award from the Canadian Institute for Health Services and Policy Research, a Canadian Institutes of Health Research New Investigator Award, and a Michael Smith Foundation for Health Research Scholar Award.

In 2015, he taught one of UBC's first [edX.org](http://edX.org) Professional Education courses on [Interrupted Time Series Analysis](#).

Prior to joining UBC, he completed a PhD in Health Policy at Harvard University and a post-doctoral fellowship at Harvard Medical School, where he trained in research methods and statistics. He has also completed an MSc from the London School of Economics, and worked as a research associate at the University of Auckland, New Zealand.

#### **Publications:**

Soumerai SB, **Law MR**. Cost-effectiveness of schizophrenia pharmacotherapy. *Am J Psychiatry* 2007;164:678.

**Law MR**, Ross-Degnan D, Soumerai SB. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. *Psychiatr Serv* 2008;59:540-6.

**Law MR**, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. *J Clin Psychiatry* 2008;69:47-53.

Soumerai SB, Zhang F, Ross-Degnan D, Ball DE, Lecates RF, **Law MR**, Hughes TE, Chapman D, Adams AS. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. *Health Aff (Millwood)* 2008;27:w185-95. Epub 2008 Apr 1.

**Law MR**, Majumdar SR, Soumerai SB. Effect of illicit direct-to-consumer advertising on use of etanercept, mometasone and tegaserod in Canada: a controlled longitudinal study. *BMJ* 2008;337:a1055.

**Law MR**, Soumerai SB, Adams AS, Majumdar SR. Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid. *Arch Intern Med.* 2009;169(21):1969-74.

---

#### **Marsha Pierre-Jacques, BS**

**2005-2007**

Ms. Pierre-Jacques' research interests included examining the relationship between health policies and access to both health care services and medicines for under-served populations including immigrants, elderly, Native Americans and low-income families. With funding from the NIH Minority Research Training Supplement Program, she pursued research in diabetes health disparities and medication non-adherence in the elderly and disabled. She also completed a project in collaboration with the World Health Organization Essential

Drugs and Medicines/Drug Action Programs assessing core indicators of pharmaceutical systems in 168 countries. Ms. Pierre-Jacques is in the process of pursuing a medical degree.

**Publications:**

World Health Organization. Carandang E, **Pierre-Jacques M**, Wagner A, Ross-Degnan D. Using Indicators to Measure Country Pharmaceutical Situations: Fact Book on WHO Level I and Level II Monitoring Indicators. WHO, Department of Technical Cooperation on Essential Drugs and Traditional Medicines, Geneva, Switzerland, December 2005.

Soumerai SB, **Pierre-Jacques M**, Zhang F, Ross-Degnan D, Adams AS, Gurwitz J, Adler G, Safran DG. Cost-related underuse of medications among the elderly and the disabled: A national survey one year before the Medicare Drug Benefit. *Arch Intern Med*. 2006;166:1829-35.

Bambauer KZ, Safran DG, Ross-Degnan D, Zhang F, Adams AS, Gurwitz J, **Pierre-Jacques M**, Soumerai SB. Depression and cost-related medication nonadherence in Medicare beneficiaries. *Archives of General Psychiatry*. 2007;64:1-7.

Madden JM, Graves AJ, Zhang F, Adams AS, Briesacher BA, Ross-Degnan D, Gurwitz JH, **Pierre-Jacques M**, Safran DG, Adler GS, Soumerai SB. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. *JAMA*. 2008;299:1922-8.

Tjia J, Briesacher B, Soumerai SB, **Pierre-Jacques M**, Zhang F, Ross-Degnan D, Gurwitz J. Medicare beneficiaries and free prescription drug samples: a national survey. *J Gen Intern Med*. 2008;23:709-14.

**Pierre-Jacques M**, Safran DG, Zhang F, Ross-Degnan D, Adams AS, Gurwitz J, Rusinak D, Soumerai SB. Reliability of new measures of cost-related medication nonadherence. *Med Care*. 2008;46:444-8.

---

**Yuting Zhang, MS, PhD**

**2005-2007**

Dr. Zhang is an Associate Professor of Health Economics and Director of the Pharmaceutical Economics Research Group in the Department of Health Policy and Management at the University of Pittsburgh Graduate School of Public Health. During her Fellowship, Dr. Zhang's research focused on examining whether using newer prescription drugs can save money by reducing use of other medical services (the drug-offset effect). She also co-lead a successful grant application to examine economic and clinical effects of prior authorization policies among Medicaid beneficiaries with bipolar disorder. Dr. Zhang received her PhD in health policy from Harvard University.

**Publications:**

**Zhang Y**. Is Cost-Saving Evidence Universal? An Economic Analysis of the International Comparison of Cost-saving Effects. (Dissertation chapter).

**Zhang Y**, Soumerai SB. Do newer prescription drugs pay for themselves? A Reassessment of the evidence. *Health Affairs* 2007;26:880-6.

**Zhang Y.** Cost-saving effects of olanzapine as long-term treatment for bipolar disorder. *J Ment Health Policy Econ.* 2008;11:135-46.

**Zhang Y,** Adams, AS, Ross-Degnan D, Zhang F, Soumerai, SB. Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder. *Psychiatr Serv* 2009;60:520-7.

---

**SeongOk Kim, PhD**

**2005-2006**

Dr. Kim is a senior researcher in the National Health Insurance Corporation of Korea where she is responsible for pharmaceutical reimbursement policies and decisions about cost-effective drug use. Her Fellowship research was funded by the Fulbright Program focused on the effects of pharmacy cost containment policies on physicians' prescribing patterns in the Korean National Health Insurance. She also interacted with colleagues at Harvard Pilgrim Health Care and Neighborhood Health Plan around pharmacy benefits policy making issues.

**Kim S.** What Factors Determine Doctors' Preferences for Original Drugs and Their Willingness to Prescribe Generic Drugs in Korea? The 6<sup>TH</sup> World Congress On Health Economics held in Copenhagen, Denmark and Lund, Sweden July 7-11, 2007. Oral Presentation.

**Kim S,** Ross-Degnan D, Adams A, Wagner A, Soumerai SB. What Factors Determine Doctors' Preferences for Originator Drugs and Their Willingness to Prescribe Generic Drugs in Korea ? (July10, 2007). iHEA 2007 6th World Congress: Explorations in Health Economics Paper. Available at SSRN: <http://ssrn.com/abstract=992638>

---

**Madeleine de Rosas-Valera, MD, MScIH (Heidelberg)**

**2005-2006**

Dr. Madeleine de Rosas-Valera is currently the Undersecretary of Health in charge of the Cluster on Health Policy, Financing, Research, International Health and National Center for Pharmaceutical Management. She is also the Chairperson for the Formulary Executive Committee and Co-Chair for the DOH Research Hub.

She is a senior health care service professional with more than two decades of professional expertise in health system and primary health care service delivery, financing and management in the public and private sectors. She has served in senior level positions with a national social health insurance organization, the Philippine Health Insurance Corporation (PHIC), responsible for Health Financing, Payment Mechanism, Contracting, Policy Development, Developing Standards of Accreditation, Developing the health care benefits package covering TB and Maternity Care and Non-Communicable Diseases, and outpatient basic care package, drug and contraceptives devices reimbursement.

Furthermore, the health sector considers Dr. Valera a champion of quality assurance, having been the leading figure in the implementation of PhilHealth's mandate of quality assurance. She has made quality assurance as her vehicle towards serving the public interest. She was A Patient Safety Technical Officer of the WHO Western Pacific Regional Office from 2009-2012.

Dr. Valera, being an outspoken advocate for rational drug use, has been recognized for her leadership in advocating the importance of cost-benefit and cost-effectiveness analyses of drugs within the Philippine health care system. She has emphasized rational drug use in PhilHealth's quality assurance program by supporting the Generics Act and adopting the



Philippine National Drug Formulary in PhilHealth's benefit payment scheme. She has also promoted the use of evidence-based medicine and HTA, particularly the clinical practice guidelines in identifying drugs and procedures that can be included in the National Health Insurance Program (NHIP) benefit based on scientific evidence. She established and strengthened linkages with the different stakeholders of NHIP especially the academe whose expertise she recruited in doing health technology assessment for PhilHealth. During her Fellowship, she developed and implemented a study of the economic burden of hospitalizations for hypertension for PhilHealth and of access to and use of antihypertensive medicines among PhilHealth members. The results of her research will inform PhilHealth as it decides how to implement outpatient medicines coverage for members with hypertension. She also studied the design of performance measures of medicines benefit policies and interacted with colleagues at Harvard Pilgrim Health Care and Neighborhood Health Plan around pharmacy benefits policy making issues.

#### **Publications:**

Wagner AK, **Valera M**, Graves AJ, Laviña S, Ross-Degnan D. Costs of hospital care for hypertension in an insured population without an outpatient medicines benefit: an observational study in the Philippines. *BMC Health Serv Res* 2008;8:161.

Kozhimannil KB, **Valera MR**, Adams AS, Ross-Degnan D. The population-level impacts of a national health insurance program and franchise midwife clinics on achievement of prenatal and delivery care standards in the Philippines. *Health Policy* 2009;92:55-64.

---

#### **Connie M. Trinacty, PhD**

**2004-2006**

Dr. Trinacty is assistant science director at the Kaiser Permanente Center for Health Research Hawaii (CHRH). Prior to joining CHRH, she was an assistant professor in population medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute, an NIH trainee and a scholar in health disparities. She earned her doctorate in health policy from Harvard University, and her master's degree in health policy and management from the Harvard School of Public Health.

During her Fellowship, Dr. Connie Trinacty was a candidate in the PhD Program in Health Policy at Harvard University. Her Fellowship research focused on issues of quality of care and self-management practices among chronically ill populations. During the first year of her Fellowship, her research focused on the impact of a quality improvement change to a diabetes health care delivery system and its impact on race-related barriers to effective care. During her second year, her research evaluated racial differences in adherence to long-term diabetes self-management practices, specifically medication use and glucose self-monitoring.

#### **Publications:**

Adams AS, Zhang F, **Mah C**, Grant RW, Kleinman K, Meigs JB, Ross-Degnan D. Race differences in long-term diabetes management in an HMO. *Diabetes Care*. 2005;28:2844-49.

Pearson SA, Soumerai SB, **Mah C**, Zhang F, Simoni-Wastila L, Salzman C, Cosler LE, Fanning T, Gallagher P, Ross-Degnan D. Racial disparities in access after regulatory surveillance of benzodiazepines. *Arch of Intern Med*. 2006;166:572-9.

**Mah C**, Soumerai SB, Adams A, Ross-Degnan D. Racial differences in impact of coverage on diabetes self-monitoring in a health maintenance organization. *Medical Care*. 2006;44:392-97.

**Trinacty CM**, Adams AS, Zhang F, Soumerai SB, Meigs J, Piette JD, Ross-Degnan D. Racial differences in long-term self-monitoring practice among newly drug-treated diabetes patients in an HMO. *JGIM*. 2007;1506-13.

Grant R, Adams AS, **Trinacty CM**, Zhang F, Kleinman K, Soumerai SB, Meigs JB, Ross-Degnan D. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. *Diabetes Care*. 2007;30(4):807-12.

Goldman RE, Sanchez-Hernandez M, Ross-Degnan D, Piette JD, **Trinacty CM**, Simon SR. Developing an automated speech-recognition telephone diabetes intervention. *Int J Qual Health Care*. 2008;20:264-70.

Adams AS, **Trinacty CM**, Zhang F, Kleinman K, Grant RW, Meigs JB, Soumerai SB, Ross-Degnan D. Medication adherence and racial differences in A1C control. *Diabetes Care*. 2008;31:916-21.

**Trinacty CM**, Adams AS, Soumerai SB, Zhang F, Meigs JB, Piette JD, Ross-Degnan D. Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort study. *BMC Health Serv Res*. 2009;9:24.

Adams AS, Zhang F, LeCates R, Graves AJ, Ross-Degnan D, Gilden D, McLaughlin T, Lu CY, **Trinacty CM**, Soumerai SB. Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees. *Arch Intern Med*. 2009;169:750-6.

---

**Kara Zivin, PhD**

**2004-2006**

Dr. Zivin is an Associate Professor, Department of Psychiatry, University of Michigan Medical School. Dr. Zivin's research applies quantitative methods to mental health services and policy with a focus on predictors and consequences of depression in older adults and among Veterans. Her research examines cost-effectiveness of depression care, mortality risks among depressed patients, employment support needs among those with mood disorders, genetic and psychosocial contributors to late-life depression, and the impact of short and long term antidepressant use and adherence on depression, health, and cost outcomes.

Dr. Zivin was the recipient of a National Institute of Mental Health (NIMH) training grant and of an individual National Research Service pre-doctoral Fellowship through NIMH. She earned her doctorate in health policy from the Harvard University Graduate School of Arts and Sciences.

Her Fellowship research focused on mental health care, in particular on the effects of a policy to improve adherence to antidepressant medications among members of Harvard Pilgrim Health Care.

**Publications:**

**Bambauer KZ**, Soumerai SB, Adams AS, Mah C, Zhang F, McLaughlin TJ. Does antidepressant adherence have an effect on glycemic control among diabetic antidepressant users? *International Journal of Psychiatry and Medicine*. 2004;34(4):289-302.

McLaughlin TJ, Aupont O, **Bambauer KZ**, Stone P, Mullan MG, Colagiovanni J, Polishuk E, Johnstone M, Locke SE. Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. *Journal of General Internal Medicine*. 2005;20(12):1084-90.

**Bambauer KZ**, Connor DF. Characteristics of aggression in clinically referred children. *CNS Spectrums*. 2005;10(9):709-18.

**Bambauer KZ**, Sabin JE, Soumerai SB. The exclusion of benzodiazepine coverage in Medicare: simple steps for avoiding a public health crisis. *Psychiatric Services*. 2005;56(9):1143-1146.

**Bambauer KZ**, Aupont O, Stone PH, Locke SE, Colagiovanni J, Mullan MG, McLaughlin TJ. The effect of a telephone counseling intervention on self-rated health of cardiac patients. *Psychosomatic Medicine*. 2005;67(4):539-45.

**Bambauer KZ**, Locke SE, Aupont O, Mullan MG, McLaughlin TJ. Using the Hospital Anxiety and Depression Scale to screen for depression in cardiac patients. *General Hospital Psychiatry*. 2005;27(4):275-84.

**Bambauer KZ**. Proposition 63: Should other states follow California's lead? *Psychiatric Services*. 2005;56(6):642-44.

**Bambauer KZ**, Johnston SC, Bambauer DE, Zivin JA. Reasons why few patients with acute stroke receive tissue plasminogen activator. *Archives of Neurology*. 2006;63:661-4.

**Bambauer KZ**, Adams AS, Zhang F, Minkoff N, Grande A, Weisblatt R, Soumerai SB, Ross-Degnan D. Physician alerts to increase antidepressant adherence: fax or fiction? *Archives of Internal Medicine*. 2006;166(5):498-504.

**Bambauer KZ**, Prigerson HG. The Stigma Receptivity Scale (SRS) and its association with mental health service use among bereaved older adults. *Journal of Nervous and Mental Disease*. 2006;194(2):139-41.

**Bambauer KZ**, Soumerai SB, Adams AS, Zhang F, Ross-Degnan D. Provider and patient characteristics associated with antidepressant nonadherence: the impact of provider specialty. *Journal of Clinical Psychiatry*. 2007 Jun;68(6):867-73.

**Bambauer KZ**, Safran DG, Ross-Degnan D, Zhang F, Adams AS, Gurwitz J, Pierre-Jacques M, Soumerai SB. Depression and cost-related medication nonadherence in Medicare beneficiaries. *Archives of General Psychiatry*. 2007 May;64(5):602-8.

**Zivin K**, Madden JM, Graves AJ, Zhang F, Soumerai SB. Cost-related medication nonadherence among beneficiaries with depression following Medicare Part D. *Am J Geriatr Psychiatry*. 2009; 17(12):1068-76.

Dr. Elliott trained as an industrial pharmacist, was one of the first critical care specialist pharmacists in the UK, and gained a Department of Health funded PhD in health economics with Prof Martin Buxton (Health Economics Research Group, Brunel University). She has been in her current position since May 2007. Prior to this she was based at the School of Pharmacy, University of Manchester (1996 to 2007).

Her Fellowship research, supported by the Commonwealth Fund Harkness Fellowship in Health Care Policy, addressed the economic impact of policies to improve adherence to medicine, as well as the barriers to taking medicines among the elderly with multiple illnesses.

**Publications:**

**Elliott RA**, Majumdar Sr, Gillick MR, Soumerai SB. Benefits and consequences for the poor and the disabled. *New England Journal of Medicine*. 2005;353(26):2739-41.

**Elliott RA**, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. *The Annals of Pharmacotherapy*. 2005;39(3):508-15.

**Elliott RA**, Ross-Degnan D, Adams AS, Safran DG, Soumerai SB. Strategies for coping in a complex world: adherence behavior among older adults with chronic illness. *J Gen Intern Med*. 2007;22(6):805-10.

Dr. Choudhry is an internist and health services researcher whose work focuses on the development and evaluation of novel strategies to improve health care quality and reduce spending. He is Professor Medicine at Harvard Medical School, the founding Executive Director of the Center for Healthcare Delivery Sciences and an Associate Physician in the Division of Pharmacoepidemiology and Pharmacoeconomics, at Brigham and Women's Hospital, where he is also a practicing hospitalist.

Dr. Choudhry received his clinical training in Ontario, and a graduate of the Harvard University PhD Program in Health Policy. His Fellowship research, supported by the Frank Knox Scholarship and a Canadian Institutes of Health Research Fellowship, addressed the impact of personal clinical experience on physician prescribing behavior.

**Publications:**

**Choudhry NK**, Fletcher RH, Soumerai SB. Systematic review: the relationship between clinical experience and quality of health care. *Annals of Internal Medicine*. 2005;142(4):260-73.

**Choudhry NK**, Anderson GM, Laupacis A, Ross-Degnan D, Normand SL, Soumerai SB. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. *British Medical Journal*. 2006;332(7534):141-5.

**Choudhry NK**, Soumerai SB, Normand SL, Ross-Degnan D, Laupacis A, Anderson GM. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. *The American Journal of Medicine*. 2006 Jul;119(7):607-15.

Dr. Donohue is Associate Professor and Vice Chair for Research in the Department of Health Policy and Management, in the Graduate School of Public Health. She is the Director of the Medicaid Research Collaborative and the Co-Director of the Center for Pharmaceutical Policy and Prescribing (CP3). She holds secondary appointments in the Clinical and Translational Science Institute and is a faculty affiliate in the Health Policy Institute and in the Center for Bioethics and Health Law.

Donohue earned a PhD in health policy from Harvard University and completed a post-doctoral fellowship in pharmaceutical policy research at Harvard Medical School. Her Fellowship research focused on the effects of pharmaceutical promotion to consumers and physicians.

**Publications:**

**Donohue JM**, Berndt ER, Rosenthal M, Epstein AM, Frank RG. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. *Medical Care*. 2004;42(12):1176-85.

**Donohue JM**, Berndt ER. Effects of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants. *Journal of Public Policy and Marketing*. 2004;23(2):115-27.

**Donohue JM**, Berndt ER. Being direct. *Marketing Health Services*. 2005;25(1):30-6.

Rosenthal MB, and **Donohue JM**. 2005. Direct-to-consumer advertising of prescription drugs: a policy dilemma. In M.A. Santoro and T.M. Gorrie (eds) *Ethics and the Pharmaceutical Industry* New York, New York: Cambridge University Press, 169-183.

Dr. Park is a pharmacist and health policy researcher. During her first Fellowship year, she examined the impact of a policy in Korea to prohibit physicians from dispensing drugs on appropriate and inappropriate prescribing of antibiotic medications. During her second year, she studied the impact of the introduction of atypical antipsychotic agents on prescribing, compliance, and the incidence of side effects among patients with schizophrenia in the UK.

She is currently a senior research fellow at Korea Institute for Health and Social Affairs. Her research interests include pharmaceutical policy, physician prescribing behaviors and pharmaceutical industry.

**Publications:**

**Park S**, Soumerai SB, Adams AS, Finkelstein JA, Jang S, Ross-Degnan D. Antibiotic use following a Korean national policy to prohibit medication dispensing by physicians. *Health Policy and Planning*. 2005;20(5):302-9.

**Park S**, Ross-Degnan D, Adams AS, Sabin J, Kanavos P, Soumerai SB. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. *British Journal of Psychiatry*. 2005;187:137-42.

---

**Elizabeth E. Roughead, BPharm, GDip Health Prom, MAppSc, PhD**

**2003-2004**

Professor Roughead's research interests include public policy on medicines, rational drug use, adverse events and pharmacoepidemiology. Her Fellowship research, supported by the Commonwealth Fund Harkness Fellowship in Health Care Policy, focused on the variability in cyclooxygenase II inhibitor prescribing in state Medicaid programs, in relationship to Medicaid prescribing restrictions. She also developed a model to integrate drug utilization, safety, and expenditure evaluation and pharmaceutical policy making for the U.S. Centers for Medicare and Medicaid Services. Following her Fellowship, she returned to the School of Pharmacy and Biomedical Sciences at the University of South Australia. She is Director of the Quality Use of Medicines and Pharmacy Research Centre, a future fellow of the Australian Research Council, Principal Investigator of the Centre of Research Excellence in Post marketing surveillance of Medicines and Medical Devices, and Executive Director of the Veterans' Medicines Advice and Therapeutics Education Services (MATES) project. She continues to serve as a member of the Australian Government advisory committee on drug utilization.

**Publications:**

**Roughead EE**, Zhang F, Ross-Degnan D, Soumerai SB. Differential effect of early or late implementation of prior authorization policies on the use of COX II inhibitors. *Medical Care*. 2006;44(4):378-82.

Zerzan JT, Morden NE, Soumerai S, Ross-Degnan D, **Roughead E**, Zhang F, Simoni-Wastila L, Sullivan SD. Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002. *Medical Care*. 2006; 44(11):1005-10.

Morden NE, Zerzan JT, Rue T, Heagerty PJ, **Roughead E E**, Soumerai S, Ross-Degnan D, Sullivan D, Medicaid Prior Authorization and Controlled-Release Oxycodone. *Medical Care*, 2008; 46(6):573-580.

---

**Siritree Suttajit, PhD**

**2003-2004**

Dr. Suttajit is a faculty member in the Pharmaceutical Care Department, Faculty of Pharmacy, Chiangmai University

She was a Ph.D. candidate at Chulalongkorn University and a Fulbright Visiting Scholar during her Fellowship year. Her research focused on the factors that influence inappropriate use of medicines in treating adult respiratory infections in a slum community in Bangkok.

**Publications:**

**Suttajit S**, Wagner AK, Tantipidoke R, Ross-Degnan D, Sitthi-amorn C. Patterns, appropriateness, and predictors of antimicrobial prescribing for adults with upper

respiratory infections in urban slum communities of Bangkok. *The Southeast Asian Journal of Tropical Medicine & Public Health*. 2005;36(2):489-97.

---

**Panos Kanavos, MSc, PhD**

**2002-2003**

Panos Kanavos (BSc, MSc (Oxon), MSc (LSE), PhD) is Reader in International Health Policy in the Department of Social Policy, London School of Economics (LSE) and Programme Director of the Medical Technology Research Group (MTRG) at LSE Health. Panos is Visiting Professor at the University of Basel, Switzerland and also has a Visiting appointment with the London School of Hygiene and Tropical Medicine (LSHTM). He has previously been a Commonwealth Foundation Harkness Fellow in Health Care Policy in the Department of Population Medicine (formerly the Department of Ambulatory Care and Prevention), Harvard Medical School. Previous visiting appointments have included the University of Lausanne and the University of Delaware. He is an Economist by training, currently coordinates the Programme in International Health Policy at LSE and teaches Health Economics, Pharmaceutical Economics and Policy, Health Care Financing, and Health Systems Performance Measurement.

Panos' research interests include comparative health policy and healthcare reform, pharmaceutical economics and policy from a developed and developing country perspective, quality and access in healthcare, and socio-economic determinants of health.

**Publications:**

Park S, Ross-Degnan D, Adams AS, Sabin J, **Kanavos P**, Soumerai SB. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. *British Journal of Psychiatry*. 2005;187:137-42.

---

**Sallie-Anne Pearson, PhD**

**2002-2003**

Sallie is a health service researcher and behavioural scientist with more than 15 years of experience in quality use of medicines research. Her interests include prescriber behaviour change, post-market surveillance of medicines and evaluating the impact of pharmaceutical policy interventions. Sallie completed her doctoral training at the University of Newcastle, Australia (1998) and her Postdoctoral Fellowship in Pharmaceutical Policy Research at Harvard Medical School (2000-2001). On her return to Australia she worked as a consultant to the WHO Collaborating Centre in Pharmaceutical Policy Boston and Medicare Australia. She established the Pharmacoepidemiology and Pharmaceutical Policy Research Group in 2006 and joined the Faculty of Pharmacy, University of Sydney in 2012. She is currently a Cancer Institute NSW Career Development Fellow.

Dr. Pearson's fellowship research focused on discriminatory effects, by race, of a state triplicate prescription program on benzodiazepine use. She also conducted a systematic review of interventions to improve medication use in health maintenance organizations.

**Publications:**

**Pearson SA**, Ross-Degnan D, Payson A, Soumerai SB. Changing medication use in managed care: a critical review of the available evidence. *American Journal of Managed Care*. 2003; 9:715-31.

**Pearson SA**, Soumerai SB, Mah C, Zhang F, Simoni-Wastila L, Salzman C, Cosler LE, Fanning T, Gallagher P, Ross-Degnan D. Racial disparities in access after regulatory surveillance of benzodiazepines. *Archives of Internal Medicine*. 2006;166(5):572-9.

Lu CY, Ross-Degnan D, Soumerai SB, **Pearson SA**. Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature – 2001-2007. *BMC Health Services Research*. 2008; 8:75.

---

**Jeanne Madden, PhD**

**2002-2003**

Dr. Madden is Associate Professor in the Department of Pharmacy and Health Systems Sciences, School of Pharmacy, Bouvé College of Health Sciences, at Northeastern University. She received a bachelor's degree in History from Brown University, a master's degree from the Harvard School of Public Health, and her doctorate from the Harvard University PhD program in Health Policy.

Dr. Madden's research primarily concerns access to health care, the burden of costs on patients, and the consequences of health system changes. She has directed several federally-funded studies examining the impact of changes in pharmacy benefits on access to treatments for chronic illness. Dr. Madden is leading a qualitative study to gather perspectives of individuals with bipolar disorder navigating different insurance benefits, and leads stakeholder engagement activities for the PCORI-sponsored parent grant evaluating the impact of high-deductible insurance plans on adolescents and adults with bipolar disorder. In her recent research as part of the Mental Health Research Network, she has led inquiries into the completeness of information in medical record data and the use of psychotropics among children with autism spectrum disorders. She is co-investigator on a study of the impact of FDA warnings about antidepressants and suicidality among youth.

Past studies have examined medication underuse and uncontrolled asthma in a commercially-insured population, access to and affordability of medicines in low- and middle-income countries, and maternal and infant outcomes following changes in hospitalization policies at childbirth. Dr. Madden has particular expertise in large datasets, measurement development and validation, and evaluation methods. She holds a secondary faculty appointment at her prior institution, the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute.

She holds a master's degree in International Health Policy and Economics from the Harvard School of Public Health and a doctoral degree from the Harvard University PhD program in Health Policy.

**Publications:**

Madden JM, Soumerai SB, Lieu TA, Mandl KD, Zhang F, Ross-Degnan D. Length-of-stay policies and ascertainment of postdischarge problems in newborns. *Pediatrics*. 2004 Jan;113(1 Pt 1):42-9.

Sinha A, Madden J, Ross-Degnan D, Soumerai S, Platt R. Reduced risk of neonatal respiratory infections among breastfed girls but not boys. *Pediatrics*. 2003 Oct;112(4):e303.



Madden JM, Soumerai SB, Lieu TA, Mandl KD, Zhang F, Ross-Degnan D. Effects on breastfeeding of changes in maternity length-of-stay policy in a large health maintenance organization. *Pediatrics*. 2003 Mar;111(3):519-24.

Madden JM, Soumerai SB, Lieu TA, Mandl KD, Zhang F, Ross-Degnan D. Effects of a law against early postpartum discharge on newborn follow-up, adverse events, and HMO expenditures. *N Engl J Med*. 2002 Dec 19;347(25):2031-8.

Madden JM, Quick JD, Ross-Degnan D, Kafle KK. Undercover careseekers: simulated clients in the study of health provider behavior in developing countries. *Soc Sci Med*. 1997 Nov;45(10):1465-82.

---

**Anita K. Wagner, PharmD, MPH, DrPH**

**2001-2002**

Dr. Anita Wagner is Associate Professor in the Department of Population Medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute in Boston, MA, USA.

For the past two decades, Dr. Wagner has contributed to or led applied research and capacity strengthening collaborations to improve—from a health systems perspective—medicines availability, access, affordability, and use, in the United States and in low and middle-income countries (LMIC). More recently, her work includes a focus on health system questions around highly priced, novel therapies.

She founded and directs the global [Medicines and Insurance Coverage \(MedIC\)](#) Initiative, which aims to support LMIC system leaders and operational staff in the design, implementation, evaluation, and routine monitoring of evidence-informed medicines policies and programs. Under the MedIC Initiative, collaborators have begun to establish a portfolio of research on pharmaceutical policies and programs in countries working toward universal health coverage (UHC).

Dr. Wagner co-directs the [Harvard Medical School Fellowship in Pharmaceutical Policy Research](#) and directs global [MedIC Courses on Medicines in Health Systems](#). More than 200 professionals from governments, academia, and other organizations in more than 20 countries have participated in the courses. In 2016, the team launched the [first online Course on Medicines in Health Systems Working Toward Universal Health Coverage](#) on the World Bank Open Learning Campus.

Dr. Wagner also serves as a pharmacoepidemiologist on the [FDA's Sentinel Initiative](#), a national system that tracks the safety of pharmaceuticals in the United States.

Dr. Wagner received her Master of Public Health degree in international health and Doctor of Public Health degree in epidemiology from the Harvard School of Public Health. She holds a doctorate in clinical pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences and a German master-equivalent degree in pharmacy.

Her Fellowship research focused on the effects of regulating psychoactive drugs in Medicaid.

**Publications:**

**Wagner AK**, Soumerai SB, Zhang F, Mah C, Simoni-Wastila L, Cosler L, Fanning T, Gallagher P, Ross-Degnan D. Effects of state surveillance on new post-hospitalization benzodiazepine use. *International Journal for Quality in Health Care*. 2003;15(5):423-31.

**Wagner AK**, Zhang F, Soumerai SB, Walker AM, Gurwitz JH, Glynn RJ, Ross-Degnan D. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? *Archives of Internal Medicine*. 2004;164(14):1567-72.

**Wagner AK**, Chan KA, Dashevsky I, Raebel MA, Andrade SE, Lafata JE, Davis RL, Gurwitz JH, Soumerai SB, Platt R. FDA drug prescribing warnings: is the black box half empty or half full? *Pharmacoepidemiology and Drug Safety*. 2006;15(6):369-86.

Simon SR, Chan KA, Soumerai SB, **Wagner AK**, Andrade SE, Feldstein AC, Lafata JE, Davis RL, Gurwitz JH. Potentially inappropriate medication use by elderly persons in U.S. Health Maintenance Organizations, 2000-2001. *Journal of the American Geriatric Society*. 2005;53(2):227-32.

**Wagner AK**, Ross-Degnan D, Gurwitz JH, Zhang F, Gilden DB, Cosler L, Soumerai SB. Effect of New York State regulatory action on benzodiazepine prescribing and hip fracture rates. *Annals of Internal Medicine*. 2007;146(2):96-103.

---

**Alyce S. Adams, PhD**

**2000-2001**

Dr. Adams is a Research Scientist II, Division of Research (DOR) and Associate Director, Health Care Delivery and Policy, Kaiser Permanente Northern California studying healthcare disparities among insured populations. Her recent publications include longitudinal studies of the impact of state Medicaid programs to reduce medication costs on medication use and outcomes among adults with disabilities and racial and ethnic disparities in diabetes self-management and outcomes in a managed care setting. Her current research focuses on understanding and reducing disparities in pain assessment, management and impact.

Prior to joining DOR, Dr. Adams was on faculty at Harvard Medical School, Boston, MA. She has served on scientific review committees for the National Institutes of Health and has received mentoring awards from Harvard Medical School and the Agency for Healthcare Research and Quality. She received her PhD in Health Policy at Harvard University and her postdoctoral training at the Department of Population Medicine (formerly the Department of Ambulatory Care and Prevention) at Harvard Medical School and Harvard Pilgrim Health Care Institute, where she holds an adjunct appointment and continues to advise students.

**Publications:**

Soumerai SB, **Adams AS**, Ross-Degnan D. Medicare prescription coverage and congressional gridlock. *J Gen Intern Med*. 2001 Dec;16(12):864-6.

Federman AD, **Adams AS**, Ross-Degnan D, Soumerai SB, Ayanian JZ. Supplemental insurance and use of effective cardiovascular drugs among elderly Medicare beneficiaries with coronary heart disease. *JAMA*. 2001 Oct 10;286(14):1732-9.

**Adams AS, Soumerai SB, Ross-Degnan D.** The case for a Medicare drug coverage benefit: a critical review of the empirical evidence. *Annu Rev Public Health.* 2001;22:49-61.  
Review.

**Adams AS, Soumerai SB, Ross-Degnan D.** Use of antihypertensive drugs by Medicare enrollees: does type of drug coverage matter? *Health Aff (Millwood).* 2001 Jan-Feb;20(1):276-86.